Table monthly_update_prescription_drug_wac

Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like C*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000392	Calliditas Therapeutics US Inc.	04/18/2025	81749000401	Tarpeyo Oral Capsule Delayed Release 4 MG 120 capsules	01/01/2025	1608.00	17850.00	01/23/2043	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000498	Catalyst Pharmaceuticals Inc	04/15/2025	69616021103	Firdapse 10mg Tablet 240/Bottle	01/01/2025	3337.78	58967.38	02/25/2037	Single Source Drug	None	None	None	1	response to recent economic conditions and inflation	None	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Firdapse: 69616021104
Rx0000498	Catalyst Pharmaceuticals Inc	04/15/2025	69616021106	Firdapse Blister shelf pack of 120 - 10mg tablets	01/01/2025	1668.89	29483.69	02/25/2037	Single Source Drug	None	None	None	1	response to recent economic conditions and inflation	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000445	Cerona Therapeutics, Inc.	03/31/2025	81643927001	Floxuridine; for injection; sterile, nonpyrogenic, lyophilized powder for reconstitution; Each vial (packaged individually) contains 500 mg of floxuridine to be reconstituted with 5 mL of sterile water for injection.	01/03/2025	131.88	3899.91	None	Innovator Multiple Source Drug	None	None	None	1	JND Therapeutics, Inc., pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000139	Chiesi USA	04/16/2025	10122051001	Curosurf® 1.5ml 80mg/mL 1 1.5mL vial - Suspension	01/01/2025	27.98	598.96	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chiesi USA believes is otherwise in the public domain or publicly available. (2) Columns N-V were intentionally left blank for this submission, as the drug was not acquired.
Rx0000139	Chiesi USA	04/16/2025	10122051003	Curosurf® 3.0ml 80mg/mL 1 3.0mL vial - Suspension	01/01/2025	55.17	1181.08	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chiesi USA believes is otherwise in the public domain or publicly available. (2) Columns N-V were intentionally left blank for this submission, as the drug was not acquired.
Rx0000139	Chiesi USA	04/11/2025	10122010150	Ferriprox ORAL SOLUTION 100mg/1mL 1 bottle of 500 mL - Solution	01/04/2025	437.84	9194.81	10/26/2029	Single Source Drug	None	None	None	1	None	1	None	1	01/06/2020	ApoPharma Inc.	None	1	None	6363.07	5843.04	2015	4533.00	None	None
Rx0000139	Chiesi USA	04/11/2025	10122010401	Ferriprox TD 1000mg FILM COATED TABLETS 1000mg 1 carton of 5 blister packs - Tablet	01/04/2025	492.49	11436.77	10/25/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquired while in development. Approved while owned by Chiesi USA.
Rx0000139	Chiesi USA	04/16/2025	10122041028	Juxtapid Oral Capsule 10 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2012	27535.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122042028	Juxtapid Oral Capsule 20 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2012	27535.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122043028	Juxtapid Oral Capsule 30 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2015	28885.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122040528	Juxtapid Oral Capsule 5 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2012	27535.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122062010	Kengreal for injection 50mg/10ML 50mg 1 carton of 10 vials - Solution	01/01/2025	467.67	10011.98	07/10/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000139	Chiesi USA	04/11/2025	76431021001	Myalept Subcutaneous Soltution Reconsituted 11.3 MG - 1 vial. Weight based dosing.	01/01/2025	277.24	6438.14	None	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	5867.52	5535.42	2014	3493.00	None	None
Rx0000139	Chiesi USA	04/11/2025	10122050201	Revcovi® (elapegademase-IvIr 1.6mg/ml) Injection 1 vial 2.4mg/1.5mL - Solution	01/04/2025	573.86	13326.36	None	Single Source Drug	None	None	None	1	None	1	None	1	11/24/2020	Leadiant Biosciences	None	1	None	10109.30	9856.00	2018	9856.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002260	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 150 MCG	01/01/2025	23.54	451.57	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	384.57	366.26	2015	255.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002360	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 300 MCG	01/01/2025	36.97	709.20	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	384.57	366.26	2015	255.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002460	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 450 MCG	01/01/2025	50.24	963.63	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	603.98	575.22	2015	401.40	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002560	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 600 MCG	01/01/2025	53.61	1028.27	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	820.66	781.58	2015	545.40	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002160	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 75 MCG	01/01/2025	23.54	451.57	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	875.70	834.00	2015	582.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002660	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 750 MCG	01/01/2025	56.37	1081.27	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	920.85	877.00	2015	612.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002760	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 900 MCG	01/01/2025	58.03	1113.08	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	947.93	902.79	2015	630.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510010010	Nucynta (Tapentadol Hydrochloride) 1 bottle of 100 Oral Tablets 100 MG	01/01/2025	247.24	1895.52	12/27/2025	Innovator Multiple Source Drug	None	None	181323520	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucyntas manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1088.71	990.64	2009	265.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510005010	Nucynta (Tapentadol Hydrochloride) 1 bottle of 100 Oral Tablets 50 MG	01/01/2025	158.77	1217.23	12/27/2025	Innovator Multiple Source Drug	None	None	181323520	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucyntas manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	699.13	636.15	2009	170.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510007510	Nucynta (Tapentadol Hydrochloride) 1 bottle of 100 Oral Tablets 75 MG	01/01/2025	185.51	1422.23	12/27/2025	Innovator Multiple Source Drug	None	None	181323520	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucyntas manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	816.86	743.28	2009	199.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510011660	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 100 MG	01/01/2025	184.40	1413.72	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	835.46	760.20	2011	269.40	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510017460	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 150 MG	01/01/2025	237.90	1823.93	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1077.89	980.79	2011	346.80	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510023260	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 200 MG	01/01/2025	302.01	2315.39	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1368.32	1245.06	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510029160	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 250 MG	01/01/2025	377.84	2896.79	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1711.91	1557.70	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510005860	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 50 MG	01/01/2025	99.71	764.41	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ERs manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	451.74	411.05	2011	145.80	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385004130	Symproic (Naldemedine Tosylate) 1 Bottle of 30 Oral Tablets 0.2 MG	01/01/2025	23.14	485.89	03/22/2029	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	415.77	395.97	2017	313.95	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	04/03/2025	00713088509	Clomid Oral Tablet 50 MG 10 per box	02/03/2025	15.64	94.27	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	04/03/2025	00713088530	Clomid Oral Tablet 50 MG 30 per box	02/03/2025	46.67	282.38	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000425	CSL Behring LLC	01/28/2025	63833082502	Berinert 500 units (500 IU / Solution / Pkg Size 1)	01/01/2025	203.41	4271.61	None	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	01/28/2025	63833082802	Haegarda 2000iu / 2000iu Solution / UOM EA = 1 vial	01/01/2025	93.10	2420.48	None	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	01/28/2025	63833082902	Haegarda 3000iu / 3000iu Solution / UOM EA = 1 vial	01/01/2025	139.64	3630.71	None	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.